Tag Archives: cvs

Sucampo Stock Hits High On EPS, But CVS Nixes Drug

Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed drug is being excluded from CVS’ (CVS) preferred formulary next year. Sucampo reported earnings of 21 cents a share, up from just 4 cents in the year-earlier quarter and 6 cents above analysts’ consensus,

Horizon Pharma Survives Through Transformation

A lot’s been going on with specialty drugmaker Horizon Pharma — so much that it’s almost a different company from what it was 12 months ago. Last July, Horizon (HZNP) learned that Express Scripts (ESRX) and CVS ‘ (CVS) Caremark were knocking its flagship drugs Vimovo and Duexis off their preferred-formulary lists on the grounds that both drugs, which combine treatments for arthritis pain with other medicines protecting against the painkillers’

Horizon Pharma Up On Bullish Leerink Initiation

Specialty drugmaker Horizon Pharma (HZNP) rose as much as 3.75 early Friday after Leerink launched coverage with an outperform rating. Analyst Jason Gerberry wrote that Horizon’s legacy brands — the arthritis medicines Vimovo and Duexis — have proved surprisingly resilient despite being removed from the preferred formularies of Express Scripts (ESRX) and CVS Health (CVS) this year. The cash flow from those brands should help the company build out